Поиск

Автор

Ключевое слово

Коллекция

Дополнительно:

Период публикации

Научный руководитель

Оппонент

По вашему запросу найдено документов: 74

Страница 1 из 8

EFFECTIVENESS AND SAFETY OF LONG-TERM TREATMENT WITH SULFONYLUREAS IN PATIENTS WITH NEONATAL DIABETES DUE TO KCNJ11 MUTATIONS: AN INTERNATIONAL COHORT STUDY

Neonatal Diabet Int Collaborative (2018)

, we did a 10-year multicentre follow-up study of a large international cohort of patients with KCNJ11

Outcomes after superficial temporal artery–middle cerebral artery anastomosis combined with multiple burr hole surgery and dural inversion synangiosis for moyamoya disease in adults

Xu, Dongxiao, Zheng, Bingjie, Wu, Qiaowei, Yao, Jinbiao, Ilyasova, Tatiana, Beilerli, Aferinc, Shi, Huaizhang (2022)

perioperative complications and follow-up outcomes, were noted. Preoperative and postoperative angiograms were

Cardiovascular Biomarkers for Prediction of in-hospital and 1-Year Post-discharge Mortality in Patients With COVID-19 Pneumonia

Motloch, LJ;, Jirak, P;, Gareeva, D;, Davtyan, P;, Gumerov, R;, Lakman, I;, Tataurov, A;, Zulkarneev, R;, Kabirov, I;, Cai, BZ;, Valeev, B;, Pavlov, V;, Kopp, K;, Hoppe, UC;, Lichtenauer, M;, Fiedler, L;, Pistulli, R;, Zagidullin, N (2022)

-cause mortality at 1 year follow-up [FU: 354 days (342; 361)]. Results: 11 patients died while hospitalized

МЕСТНАЯ И ОБЩАЯ РЕАКЦИИ ПРИ ВВЕДЕНИИ ВАКЦИНЫ ПРОТИВ COVID-19

LOCAL AND SYSTEMIC ADVERSE REACTIONS FOLLOWING COVID-19 VACCINE

Zherebtsova, N.Yu., Kajdanek, T.V., Жеребцова, Н.Ю., Кайданек, Т.В. (2022)

LOCAL AND SYSTEMIC ADVERSE REACTIONS FOLLOWING COVID-19 VACCINE

Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors

Motloch, L.J., Jirak, Peter, Mirna, Moritz, Fiedler, Lukas, Davtyan, P.A., Lakman, I.A., Gareeva, D.F., Tyurin, A.V., Gumerov, R.M., Matskeplishvili, S.T., Pavlov, V.N., Cai, Benzhi, Kopp, Kristena, Topf, Alberta, Hoppe, Uta C., Pistulli, Rudini, Zagidullin, N.S. (2022)

follow-up (393 ± 87 days) of 1,746 consecutive patients, hospitalized with and surviving COVID-19

Safety, Efficacy and Long-Term Outcomes of Patients Treated with the Occlutech Paravalvular Leak Device for Significant Paravalvular Regurgitation

Onorato, EM, Alamanni, F, Muratori, M, Smolka, G, Wojakowski, W, Pysz, P, Zorinas, A, Zakarkaite, D, Eltchaninoff, H, Litzer, PY, Godart, F, Calvert, P, Christou, C, Mussayev, A, Missiroli, B, Buzaev, I, Curello, S, Tesorio, T, Bartorelli, AL (2022)

80% at baseline to 14.1% at 2-year follow-up (FAS). The proportion of FAS patients needing hemolysis

Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

Alexeeva, E, Horneff, G., Dvoryakovskaya, T., Denisova, R., Nikishina, I., Zholobova, E., Malievskiy, V., Santalova, G., Stadler, E., Balykova, L., Spivakovskiy, Y., Kriulin, I., Alshevskaya, A., Moskalev, A. (2021)

) or placebo+MTX (n = 33) for up to 24 weeks, followed by a 24-week open-label phase. The efficacy endpoints

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III OR IV HODGKIN'S LYMPHOMA

. The key secondary end point was overall survival. RESULTS At a median follow-up of 24.6 months, 2-year

FLUOXETINE FOR STROKE RECOVERY META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

MEAD, G.E., LEGG, L., TILNEY, R., HSIEH, C.F., WU, S., LUNDSTRÖM, E., RUDBERG, A.S., KUTLUBAEV, M., DENNIS, M.S., SOLEIMANI, B., BARUGH, A., HACKETT, M.L., HANKEY, G.J. (2020)

and follow-up, with the same number or fewer adverse effects. Methods: Searches (from 2012) in July 2018

Improvement of brain perfusion in patients with chronic brain ischemia at epidural spinal cord electrical stimulation

Zhao, S., Sufianova, G., Shapkin, A., Mashkin, A., Meshcheryakova, S., Han, DY (2022)

preserved during the follow-up examination 1 year after the implantation of chronic SCS system. The greatest

Страница 1 из 8